Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer

Hoyle, Alex; Ali, Sumia; James, Nicholas D.; Parker, Chris; Cook, Adrian; Attard, Gerhardt; Cross, William; Dearnaley, David P.; Bono, Johann S. de; Gilson, Clare; Gillessen, Silke; Jones, Robert J.; Matheson, David; Mason, Malcolm David; Ritchie, A. W. S.; Russell, Marion H.; Parmar, Mahesh; Sydes, Matthew R.; Clarke, Noel W.

doi:10.1093/annonc/mdy424.033

Cited by 22 publications

(21 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The STAMPEDE investigators recently conducted a post-hoc analysis of all metastatic patients enrolled into the abiraterone comparison, classifying patients by metastatic extent according LATITUDE and CHAARTED criteria (Table 3) [13]. The posthoc analysis demonstrated that, according to the LATITUDE criteria, 428 patients (48%) were identified as having LV disease, of Data shown correspond to subgroup of metastatic patients in the STAMPEDE trials.…”

Section: Adt 1 Cyp17 Inhibition (Abiraterone)mentioning

confidence: 99%

“…d Based on post-hoc analysis of only metastatic patients in STAMPEDE abiraterone trial, diagnosed with conventional imaging and available Gleason score, n ¼ 901. Analysis was carried out by Hoyle et al [13].…”

Section: Adt 1 Radiotherapy To the Primary Tumormentioning

confidence: 99%

“…Nonetheless, across trial comparisons remain difficult due to different inclusion criteria and patient populations. Even when only the HV patients of CHAARTED and LATITUDE were compared, still 18% of patients had been risk-stratified differently based on disease volume, using both studies' inclusion criteria (Table 3) [13]. While this field is pending the results of the direct comparison of the ongoing trials, considerations extracted from the subgroup/posthoc analyses of the CHAARTED/STAMPEDE/LATITUDE trials is the best available evidence, but should be interpreted with caution.…”

Section: Considerations Based On the Trial Data Of Current Agents Incmentioning

confidence: 99%

“…Trials have been conducted in slightly different patient populations. Unfortunately, no biomarkers are available, leaving the treatment choice based on clinical symptoms, patients' preference, experience, toxicity and costs; however, stratification of patients by disease burden seems to be a possible factor for treatment selection, since the recently published post-hoc analysis of the STAMPEDE abiraterone trial showed a survival benefit in low-volume (LV) mCNPC patients, which has not been substantially established by the addition of docetaxel [13]. The latest insights include the benefit of local radiotherapy to the prostate in LV disease patients, and the OS benefit obtained by the addition of apalutamide or enzalutamide to ADT in mCNPC patients [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?

et al. 2019

View full text Add to dashboard Cite

Androgen-deprivation therapy (ADT) has been the mainstay of treatment of metastatic prostate cancer since the first report of its hormonal dependence in the 1940s. Since 2015, the addition of docetaxel and the addition of abiraterone to ADT have conferred substantial overall survival benefit in men with metastatic castration-naïve prostate cancer (mCNPC). The shift of these treatment options for metastatic prostate cancer from the castration-resistant setting to the castration-naïve setting has led to new challenges in the management of this disease. It remains to be determined which patients may benefit most from either early concomitant docetaxel or from abiraterone with ADT, since biomarkers for early therapy response and risk stratification are currently lacking. Therefore, the ability to personalize medicine is hampered. Furthermore, the earlier detection of metastatic prostate cancer by using new imaging modalities makes the application of clinical trial results in daily practice increasingly challenging. Recently, both local radiotherapy to the primary tumor combined with ADT and abiraterone combined with ADT showed a survival benefit in low-volume disease patients. The latest data also demonstrated a survival benefit with the addition of apalutamide or enzalutamide to ADT. The extent of metastatic disease may become one of the most important factors to determine treatment choice. In this review article, we summarize trial data to provide guidance for treatment selection in metastatic castration-naïve prostate cancer.

show abstract

Section: Adt 1 Cyp17 Inhibition (Abiraterone)mentioning

confidence: 99%

Section: Adt 1 Radiotherapy To the Primary Tumormentioning

confidence: 99%

Section: Considerations Based On the Trial Data Of Current Agents Incmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…At the ESMO 2018 data on the Arm G of the STAMPEDE trial revealing the impact of abiraterone acetate + prednisone in 901 patients with both high-risk but also low-risk hormone sensitive primary metastatic PCa have been presented. In general, STAMPEDE is a multi-arm, multi-stage design trial, assessing various drugs and outcomes in patients starting on long-term ADT with M1 or high-risk M0 disease [7]. The primary endpoint of the study was to evaluate heterogeneity of abiraterone acetate + prednisone effect OS and failure-free survival (FFS).…”

Section: Hormone-sensitive Diseasementioning

confidence: 99%

ESMO 2018—personal highlights

Heidegger

Hilbe

Pircher

2019

memo

View full text Add to dashboard Cite

This article intends to summarize personal highlights of the ESMO (European Society for Medical Oncology) 2018 meeting and does not aim to give a comprehensive overview. We will summarize the most recent presented data on the treatment of non-small cell lung establishing first-line combinational therapies (chemotherapy backbone with immunotherapy) as standard of care. Furthermore highly practice relevant data on the treatment of recurrent or metastatic head and neck squamous cell carcinoma were presented. Next the treatment landscape of metastatic prostate cancer is changing rapidly and some new aspects in metastatic disease are reported.

show abstract

Chemotherapeutic Agents for Urologic Oncology: Basic Principles

Gleave

2020

Urologic Principles and Practice

View full text Add to dashboard Cite

Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer

Cited by 22 publications

References 0 publications

Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?

Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?

ESMO 2018—personal highlights

Chemotherapeutic Agents for Urologic Oncology: Basic Principles

Contact Info

Product

Resources

About